Ipsen SA is showing no sign of slowing down on the dealmaking front and has bagged the ex-US licensing rights to Day One Biopharmaceuticals, LLC's recently approved brain cancer drug, Ojemda.
Take Five: Ipsen Bags Rights To Day One Brain Cancer Drug
The Paris-based group has inked five external deals already this year, this time paying $111m to get access internationally to Day One Biopharmaceuticals' Ojemda for refractory pediatric low-grade glioma.
